MCID: BSL006
MIFTS: 40

Basaloid Squamous Cell Carcinoma malady

Category: Cancer diseases

Aliases & Classifications for Basaloid Squamous Cell Carcinoma

About this section

Aliases & Descriptions for Basaloid Squamous Cell Carcinoma:

Name: Basaloid Squamous Cell Carcinoma 10 12 65
 
Basaloid Carcinoma 10 65

Classifications:



External Ids:

Disease Ontology10 DOID:5522
SNOMED-CT59 128634009
NCIt42 C54244
UMLS65 C1266005, C1704216

Summaries for Basaloid Squamous Cell Carcinoma

About this section
Disease Ontology:10 A squamous cell carcinoma that has a solid, closely packed growth of cells with hyperchromatic nuclei, scant cytoplasm, small cystic spaces, and foci of necrosis. It has overlying squamous dysplasia, rare foci of overt keratinization, and/or coexistent keratinizing squamous cell carcinoma.

MalaCards based summary: Basaloid Squamous Cell Carcinoma, also known as basaloid carcinoma, is related to acute pancreatitis and molluscum contagiosum. An important gene associated with Basaloid Squamous Cell Carcinoma is KRT14 (Keratin 14), and among its related pathways are Inhibition of Ribosome Biogenesis by p14(ARF) and Oncogene Induced Senescence. Affiliated tissues include prostate, thyroid and t cells, and related mouse phenotypes are hearing/vestibular/ear and pigmentation.

Related Diseases for Basaloid Squamous Cell Carcinoma

About this section

Diseases related to Basaloid Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 281)
idRelated DiseaseScoreTop Affiliating Genes
1acute pancreatitis30.6CDKN2A, TP53
2molluscum contagiosum30.4CDKN2A, TP53
3pancreatic cancer30.2CDKN2A, EGFR, TP53
4hartnup disorder30.2CDKN2A, EGFR, TP53
5esophageal basaloid squamous cell carcinoma12.6
6cervical basaloid squamous cell carcinoma12.6
7vulvar basaloid squamous cell carcinoma12.6
8anus basaloid carcinoma12.5
9thymus basaloid carcinoma12.4
10penis basaloid carcinoma12.3
11basaloid squamous cell skin carcinoma11.6
12endotheliitis10.4
13spinal cord astrocytoma10.4CDKN2A, TP53
14deep leiomyoma10.4CDKN2A, TP53
15splenogonadal fusion limb defects micrognatia10.4CDKN2A, TP53
16basaloid squamous cell carcinoma10.4CDKN2A, TP53
17chronic rhinitis10.4CDKN2A, TP53
18myotonia congenita10.4CDKN2A, TP53
19middle ear squamous cell carcinoma10.4CDKN2A, TP53
20anal paget's disease10.4CDKN2A, TP53
21renal pelvis squamous cell carcinoma10.4CDKN2A, TP53
22hepatopulmonary syndrome10.4CDKN2A, TP53
23spastic ataxia 210.4CDKN2A, TP53
24peroxisomal disease10.3CDKN2A, TP53
25cervical verrucous carcinoma10.3CDKN2A, TP53
26apocrine adenocarcinoma10.3CDKN2A, TP53
27benign mesenchymoma10.3CDKN2A, TP53
28basophilic carcinoma10.3CDKN2A, TP53
29vulva verrucous carcinoma10.3CDKN2A, TP53
30recessive dystrophic epidermolysis bullosa-generalized other10.3CDKN2A, TP53
31substance abuse10.3KRT14, TP53
32gastrointestinal neuroendocrine tumor10.3CDKN2A, TP53
33variola minor10.3KRT14, KRT4
34sebaceous adenocarcinoma10.3KRT14, TP63
35childhood pilocytic astrocytoma10.3CDKN2A, TP53
36progressive muscular atrophy10.3CDKN2A, TP53
37schwannoma of twelfth cranial nerve10.3CDKN2A, TP53
38anhidrosis10.3KRT14, TP63
39microglandular adenosis10.3ENG, TP53
40bilateral breast cancer10.3CDKN2A, TP53
41breast cancer10.3
42arthritis10.3
43autoimmune hepatitis10.3
44b-cell lymphomas10.3
45diffuse large b-cell lymphoma10.3
46hepatitis10.3
47leukemia10.3
48liver disease10.3
49lymphoma10.3
50candidiasis10.3

Graphical network of the top 20 diseases related to Basaloid Squamous Cell Carcinoma:



Diseases related to basaloid squamous cell carcinoma

Symptoms for Basaloid Squamous Cell Carcinoma

About this section

Drugs & Therapeutics for Basaloid Squamous Cell Carcinoma

About this section

Drugs for Basaloid Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
FluorouracilapprovedPhase 3, Phase 2, Phase 1168451-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
2
CisplatinapprovedPhase 3, Phase 2, Phase 1254015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatin
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinol-aq
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
3Immunologic FactorsPhase 3, Phase 218483
4Nucleic Acid Synthesis InhibitorsPhase 3, Phase 23836
5Alkylating AgentsPhase 3, Phase 23582
6MitomycinsPhase 3, Phase 2219
7Immunosuppressive AgentsPhase 3, Phase 210422
8Antimetabolites, AntineoplasticPhase 3, Phase 25770
9Antibiotics, AntitubercularPhase 3, Phase 25971
10Anti-Bacterial AgentsPhase 3, Phase 29140
11AntimetabolitesPhase 3, Phase 29454
12
CarboplatinapprovedPhase 2, Phase 1188541575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
13
Capecitabineapproved, investigationalPhase 21220154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
14
CetuximabapprovedPhase 2, Phase 1713205923-56-456842117, 2333
Synonyms:
205923-56-4
Anti EGFR
Cetuximab
Cetuximab (USAN/INN)
Cetuximab (genetical recombination)
 
Cetuximab (genetical recombination) (JAN)
D03455
Erbitux
Erbitux (TN)
IMC-C225
cetuximab
15
PaclitaxelapprovedPhase 2, Phase 1262133069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
16
SuccinylcholineapprovedPhase 2141306-40-15314
Synonyms:
2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM)
2,2'-[(1,4-DIOXOBUTANE-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)
2ha2
2ha6
306-40-1
4-04-00-01451 (Beilstein Handbook Reference)
541-19-5 (diiodide)
55-94-7 (dibromide)
71-27-2 (dichloride)
AC1L1K2T
Anectine
BRN 1805311
C07546
C14H30N2O4
CHEBI:45652
CHEMBL703
CID5314
Choline, succinate (2:1) (ester)
Choline, succinate (ester)
DB00202
Diacetylcholine
Dicholine succinate
Ditilin
Ditiline
HMS2090P14
HSDB 3254
InChI=1/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
L000926
LS-53328
Listenon
 
Lopac-S-8251
Lopac0_001080
Lysthenon
MolPort-002-964-486
NCGC00015971-01
NCGC00015971-03
NCGC00162336-01
Quelicin
Quelicin Preservative Free
SCK
ST50437287
STK177290
Scoline
Succicuran
Succinic acid, diester with choline
Succinic acid, diester with choline chloride
Succinocholine
Succinoylcholine
Succinyl choline
Succinylbischoline
Succinylcholine
Succinylcholine Chloride
Succinyldicholine
Sucostrin
Suxamethonium
Suxamethonium chloride
UNII-J2R869A8YF
ZINC01530820
succinylcholine
succinyldicholine
trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio
trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium
17Peripheral Nervous System AgentsPhase 218510
18Tubulin ModulatorsPhase 2, Phase 14279
19Antimitotic AgentsPhase 2, Phase 14296
20Albumin-Bound PaclitaxelPhase 2, Phase 12621
21Antineoplastic Agents, PhytogenicPhase 2, Phase 14294
22Neuromuscular AgentsPhase 2922
23Neuromuscular Depolarizing AgentsPhase 2116
24Neuromuscular Blocking AgentsPhase 2327
25
Docetaxelapproved, investigational, Approved May 1996Phase 11844114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docefrez
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8

Interventional clinical trials:

idNameStatusNCT IDPhase
1Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal CancerCompletedNCT00003596Phase 3
2Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal CancerCompletedNCT00025090Phase 3
3Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal CancerActive, not recruitingNCT00003652Phase 3
4Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal CancerRecruitingNCT02560298Phase 2
5Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal CancerRecruitingNCT00316888Phase 2
6Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and NeckActive, not recruitingNCT00570674Phase 1, Phase 2
7Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal CancerActive, not recruitingNCT00324415Phase 2
8Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal CancerActive, not recruitingNCT00423293Phase 2
9Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and NeckActive, not recruitingNCT00513383Phase 1

Search NIH Clinical Center for Basaloid Squamous Cell Carcinoma

Genetic Tests for Basaloid Squamous Cell Carcinoma

About this section

Anatomical Context for Basaloid Squamous Cell Carcinoma

About this section

MalaCards organs/tissues related to Basaloid Squamous Cell Carcinoma:

33
Prostate, Thyroid, T cells, Endothelial, Testis, Breast, Skin

Animal Models for Basaloid Squamous Cell Carcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Basaloid Squamous Cell Carcinoma:

38 (show all 23)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053778.8EGFR, GJA1, KRT14, TP53
2MP:00011868.3CDKN2A, EGFR, KRT14, KRT4, PTCH1, TP53
3MP:00053718.1EGFR, GJA1, PTCH1, TP53, TP63
4MP:00020067.9CDKN2A, EGFR, KRT14, PTCH1, TP53, TP63
5MP:00030127.6CDKN2A, EGFR, GJA1, PTCH1, TP53, TP63
6MP:00028737.6EGFR, ENG, GJA1, PTCH1, TP53, TP63
7MP:00053797.4CDKN2A, EGFR, GJA1, KRT14, PTCH1, TP53
8MP:00053817.4CDKN2A, EGFR, KRT14, KRT4, PTCH1, TP53
9MP:00053897.4CDKN2A, EGFR, GJA1, KRT14, PTCH1, TP53
10MP:00053807.3CDKN2A, EGFR, ENG, GJA1, PTCH1, TP53
11MP:00053847.3CDKN2A, EGFR, GJA1, KRT14, PTCH1, TP53
12MP:00053907.3CDKN2A, EGFR, GJA1, PTCH1, TP53, TP63
13MP:00053697.1CDKN2A, EGFR, ENG, GJA1, PTCH1, TP53
14MP:00053977.0CDKN2A, EGFR, ENG, GJA1, KRT14, PTCH1
15MP:00053916.9CDKN2A, EGFR, GJA1, KRT14, KRT4, PTCH1
16MP:00053886.9CDKN2A, EGFR, ENG, GJA1, KRT14, PTCH1
17MP:00053856.9CDKN2A, EGFR, ENG, GJA1, PTCH1, TP53
18MP:00053876.8CDKN2A, EGFR, GJA1, KRT14, PTCH1, TP53
19MP:00053766.8CDKN2A, EGFR, ENG, GJA1, KRT14, PTCH1
20MP:00053826.7EGFR, ENG, GJA1, KRT14, KRT4, PTCH1
21MP:00107716.5CDKN2A, EGFR, ENG, GJA1, KRT14, KRT4
22MP:00107686.3CDKN2A, EGFR, ENG, GJA1, KRT14, KRT4
23MP:00053786.2CDKN2A, EGFR, ENG, GJA1, KRT14, KRT4

Publications for Basaloid Squamous Cell Carcinoma

About this section

Articles related to Basaloid Squamous Cell Carcinoma:

(show top 50)    (show all 170)
idTitleAuthorsYear
1
46,XY disorders of sex development and congenital diaphragmatic hernia: A case with dysmorphic facies, truncus arteriosus, bifid thymus, gut malrotation, rhizomelia, and adactyly. (25898814)
2015
2
Superior Mesenteric Artery Syndrome in a 20-year-old Athletic Female with Abdominal Pain. (26612308)
2015
3
YKL-40 induces IL-8 expression from bronchial epithelium via MAPK (JNK and ERK) and NF-I_B pathways, causing bronchial smooth muscle proliferation and migration. (23197259)
2013
4
Propranolol treatment of portal hypertension in cirrhosis patients is better the higher the untreated pressure: a single-centre prospective experience. (23755897)
2013
5
Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice. (23926350)
2013
6
Validity and reliability of radiological methods to assess proximal hip geometry in children with cerebral palsy: a systematic review. (23731365)
2013
7
Fuller Albright, postmenopausal osteoporosis, and fish vertebrae. (23882094)
2013
8
Acrodermatitis enteropathica-like skin lesions in a neonate. (23814231)
2013
9
Proteomic analysis reveals new cardiac-specific dystrophin-associated proteins. (22937058)
2012
10
Cacnb4 directly couples electrical activity to gene expression, a process defective in juvenile epilepsy. (22892567)
2012
11
Adolescent opioid abuse. (22945324)
2012
12
Hemidystonia in uncontrolled type 2 diabetes mellitus. (21555647)
2011
13
High correlation of scotopic and photopic electroretinogram components with severity of central retinal artery occlusion. (21339804)
2011
14
Excess risk of adverse pregnancy outcomes in women with porphyria: a population-based cohort study. (20978938)
2011
15
Letter: Generalized lichen nitidus successfully treated with pimecrolimus 1 percent cream. (21810396)
2011
16
Trans-Atlantic debate: is carotid artery disease responsible for perioperative strokes after coronary artery bypass surgery? (21166076)
2010
17
Lipid droplet-associated proteins in steatosis. Effects of induction and siRNA-mediated downregulation of PAT proteins in cell culture models of hepatocyte steatosis]. (20661576)
2010
18
Nodular amelanotic melanoma. (20445300)
2010
19
The I-neb Adaptive Aerosol Delivery System enhances delivery of alpha1-antitrypsin with controlled inhalation. (20373910)
2010
20
Assembly of nuclear pore complexes mediated by major vault protein. (19240118)
2009
21
Malignant hematopoietic cell lines: in vitro models for the study of WaldenstrAPm's macroglobulinemia. (18533260)
2008
22
Association between the paraoxonase-1 192Q>R allelic variant and coronary endothelial dysfunction in patients with early coronary artery disease. (18241625)
2008
23
A case of adenomatoid tumor of the testis treated by testis-sparing surgery: a case report]. (18546867)
2008
24
Recent advances in the therapy of renal cancer. (17250461)
2007
25
Effect of APOE polymorphisms on early responses to traumatic brain injury. (16997460)
2006
26
NXP-2 association with SUMO-2 depends on lysines required for transcriptional repression. (16567619)
2006
27
Structural comparison of human C4A3 and C4B1 after proteolytic activation by C1s. (16098595)
2006
28
Parotitis associated with a parainfluenza virus type 3 infection during aplasia after unrelated allogeneic stem cell transplantation. (16966297)
2006
29
A case of osteoclast-like giant cell tumor of the pancreas with ductal adenocarcinoma: histopathological, immunohistochemical, ultrastructural and molecular biological studies. (15953882)
2005
30
Periosteal chondrosarcoma in a 9-year-old girl with osteochondromatosis. (15723209)
2005
31
Occurrence of del(GIB6-D13S1830) mutation in Italian non-syndromic hearing loss patients carrying a single GJB2 mutated allele. (15219044)
2004
32
The Wnt antagonist sFRP1 in colorectal tumorigenesis. (14871816)
2004
33
C825T polymorphism of the G protein beta3 subunit is associated with obesity but not with insulin sensitivity. (15090636)
2004
34
The polymorphic human glutathione transferase T1-1, the most efficient glutathione transferase in the denitrosation and inactivation of the anticancer drug 1,3-bis(2-chloroethyl)-1-nitrosourea. (11841793)
2002
35
A site in the complement receptor 2 (CR2/CD21) silencer is necessary for lineage specific transcriptional regulation. (11312253)
2001
36
Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. (11748108)
2001
37
Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol. (11129731)
2000
38
Hyperglycosylated human chorionic gonadotropin (invasive trophoblast antigen) immunoassay: A new basis for gestational Down syndrome screening. (10585342)
1999
39
Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors. (9660477)
1998
40
Hypothalamic pilocytic astrocytoma presenting with intratumoral and subarachnoid hemorrhage. (9414929)
1997
41
Coronary restenosis. (8788732)
1996
42
Pathogenesis of essential hypertension--present views. (9112629)
1996
43
Fibrogenesis imperfecta ossium. (7559718)
1995
44
Synthetic lipopeptide Pam3CysSer(Lys)4 is an effective activator of human platelets. (8023898)
1994
45
Characterization of the tachykinin neurokinin-2 receptor in the human urinary bladder by means of selective receptor antagonists and peptidase inhibitors. (8246132)
1993
46
Correction of mucolipidosis III in vitro by gene transfer. (8288225)
1993
47
Increased apolipoprotein E and c-fms gene expression without elevated interleukin 1 or 6 mRNA levels indicates selective activation of macrophage functions in advanced human atheroma. (1557388)
1992
48
Mononuclear cells enhance prostaglandin E2 production of polymorphonuclear leukocytes via tumor necrosis factor alpha. (2334439)
1990
49
Chronic paroxysmal hemicrania. (2726045)
1989
50
Cystic nephroma. (199349)
1977

Variations for Basaloid Squamous Cell Carcinoma

About this section

Expression for genes affiliated with Basaloid Squamous Cell Carcinoma

About this section
Search GEO for disease gene expression data for Basaloid Squamous Cell Carcinoma.

Pathways for genes affiliated with Basaloid Squamous Cell Carcinoma

About this section

GO Terms for genes affiliated with Basaloid Squamous Cell Carcinoma

About this section

Cellular components related to Basaloid Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1keratin filamentGO:00450959.7KRT14, KRT4

Biological processes related to Basaloid Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1replicative senescenceGO:00903999.8CDKN2A, TP53
2DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:00069789.7TP53, TP63
3cell agingGO:00075699.7TP53, TP63
4hair follicle developmentGO:00019429.7EGFR, TP63
5intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorGO:00427719.7TP53, TP63
6positive regulation of osteoblast differentiationGO:00456699.5GJA1, TP63
7negative regulation of cell growthGO:00303089.4CDKN2A, GJA1, TP53
8keratinocyte proliferationGO:00436169.3PTCH1, TP63
9regulation of cell proliferationGO:00421278.9EGFR, ENG, PTCH1
10epithelial cell differentiationGO:00308558.6KRT14, KRT4, TP63
11apoptotic processGO:00069158.5CDKN2A, GJA1, TP53, TP63
12positive regulation of transcription from RNA polymerase II promoterGO:00459447.9CDKN2A, EGFR, ENG, TP53, TP63

Molecular functions related to Basaloid Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1ubiquitin protein ligase bindingGO:00316259.6EGFR, TP53

Sources for Basaloid Squamous Cell Carcinoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet